Alterations of Cerebral Metabolism in Patients with Diabetes Mellitus Studied by Proton Magnetic Resonance Spectroscopy

 

 Buy Article Permissions and Reprints

Abstract

To evaluate possible pathophysiologic links between cerebral changes in diabetic patients detected by proton magnetic resonance spectroscopy and clinical as well as laboratory parameters.

The brains of 30 patients with diabetes mellitus and 30 healthy volunteers were examined using a STEAM sequence (TR 1500 ms, TE 20 ms). We measured in occipital gray matter and parietal white matter in a 1.5-Tesla magnet. Laboratory parameters were acquired before and after the examination.

In diabetic patients a significant elevation of the myo-inositol/creatine ratio in gray and white matter was present (p = 0.006). Choline/creatine ratio in gray matter was elevated compared to normal controls (p = 0.002). No correlation with laboratory parameters was detected. Myo-inositol was even more elevated in patients with polyneuropathy (p = 0.024). No correlation with age or sex was detected.

The changes found in diabetes are similar to those found in patients with Alzheimer's disease, dialysis, and after renal transplant, suggesting a similar etiology. Elevated myo-inositol may not only indicate osmolar changes in glial cells but also glial cell alteration due to amyloid or amylin deposition with formation of neurofibrillary tangles, especially as these changes are found in all of these diseases and no correlation to osmolar deterioration exists.

References

• 1 American Diabetes Association . Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy.  Diabetes Care. 1988;  11 592-597
  PubMedGoogle Scholar
• 2 Araki Y, Nomura M, Tanaka H, Yamamoto H, Yamamoto T, Tsukaguchi I, Nakamura H. MRI of the brain in diabetes mellitus.  Neuroradiology. 1994;  36 101-103
  CrossrefPubMedGoogle Scholar
• 3 Arieff A I, Kleeman C R. Studies on mechanisms of cerebral edema in diabetic comas: Effects of hyperglycemia and rapid lowering of plasma glucose in normal rabbits.  J Clin Invest. 1973;  52 571-583
  PubMedGoogle Scholar
• 4 Banks W A, Kastin A J, Maness L M, Huang W, Jaspan J B. Permeability of the blood brain barrier to amylin.  Life Science. 1995;  57 1993-2001
  CrossrefPubMedGoogle Scholar
• 5 Behar K L, Boucher R, Fritch W, Manuelidis L. Changes in N-Acetylaspartate and Myo-inositol detected in the cerebral cortex of hamsters with Creutzfeld-Jakob disease.  Magn Res Imag. 1998;  16 963-968
  CrossrefPubMedGoogle Scholar
• 6 Charge S BP, Esiri M M, Bethune C, Hansen B C, Clark A. Apolipoprotein E is associated with islet amyloid and other amyloidoses. Implications for Alzheimer's disease.  J Path. 1996;  179 443-447
  PubMedGoogle Scholar
• 8 Geissler A, Fründ R, Kohler S, Eichhorn H M, Krämer B K, Feuerbach S. Abnormalities in cerebral metabolite patterns in dialysis patients detected with H-1 MR spectroscopy.  Radiology. 1995;  194 693-697
  PubMedGoogle Scholar
• 9 Greene D A, Sima A A, Stevens M J, Feldman E L, Lattimer S A. Complications: neuropathy, pathogenetic considerations.  Diabetes Care. 1992;  15 1902-1925
  PubMedGoogle Scholar
• 10 Hanefeld F, Kruse B, Holzbach U, Christen H J, Merboldt K D, Hanicke W, Frahm J. Hemimegalencephaly: localized proton magnetic resonance spectroscopy in vivo.  Epilepsia. 1995;  36 1215-1241
  PubMedGoogle Scholar
• 11 Häussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, Gerok W, Hennig J. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy.  Gastroenterology. 1994;  107 1475-1480
  PubMedGoogle Scholar
• 12 Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.  J Neurol Transm. 1998;  105 415-422
  CrossrefPubMedGoogle Scholar
• 13 Kamba M, Inoue Y, Higami S, Suto Y, Ogawa T, Chen W. Cerebral metabolic impairment in patients with obstructive sleep apnoea: an independent association of obstructive sleep apnoea with white matter change.  J Neurol Neurosurg Psychiatry. 2001;  71 334-339
  CrossrefPubMedGoogle Scholar
• 14 Kernbach G, Puschel K, Brinkmann B. Biochemical measurements of glucose metabolism in relation to cause of death and postmortem effects.  Z Rechtsmed. 1986;  96 199-213
  PubMedGoogle Scholar
• 15 Kreis R, Ross B D. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy.  Radiology. 1992;  184 123-130
  PubMedGoogle Scholar
• 16 Lien Y H, Shapiro J I, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis.  J Clin Invest. 1991;  8 303-309
  PubMedGoogle Scholar
• 17 Loes D J, Biller J, Hart M N, Godersky J C, Adams H P, Keefauver S P, Tranel D. Leukoencephalopathy in cerebral amyloid angiopathy: MR imaging in four cases.  AJNR. 1990;  11 485-488
  PubMedGoogle Scholar
• 18 Lorenzo A, Razzaboni B, Weir G C, Yankner B A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.  Nature. 1994;  368 756-760
  CrossrefPubMedGoogle Scholar
• 20 Mann D M. The topographic distribution of brain atrophy in Alzheimer's disease.  Acta Neuropathol Berl. 1991;  83 81-86
  CrossrefPubMedGoogle Scholar
• 21 Miller B L, Moats R A, Shonk T, Ernst T, Woolley S, Ross B D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy.  Radiology. 1993;  187 433-437
  PubMedGoogle Scholar
• 22 Owen O E, Trapp V E, Skutches C L, Mozzoli M A, Hoeldtke R D, Boden G, Reichard Jr G A. Acetone metabolism during diabetic ketoacidosis.  Diabetes. 1982;  31 242-248
  CrossrefPubMedGoogle Scholar
• 23 Reichard Jr G A, Skutches C L, Hoeldtke R D, Owen O E. Acetone metabolism in humans during diabetic ketoacidosis.  Diabetes. 1986;  35 668-674
  PubMedGoogle Scholar
• 24 Roser W, Stock K W. 1-H MRS of liver and brain in a patient with AL amyloidosis.  Magn Reson Imaging. 1997;  15 993-996
  PubMedGoogle Scholar
• 25 Ross B M, Moszczynska A, Blusztajn J K, Sherwin A, Lozano A, Kish S J. Phospholipid biosynthetic enzymes in human brain.  Lipids. 1997;  32 351-358
  CrossrefPubMedGoogle Scholar
• 26 Scarpini E, Bianchi R, Moggio M, Sciacco M, Fiori M G, Scarlato G. Decrease of nerve Na+, K(+)-ATPase activity in the pathogenesis of human diabetic neuropathy.  J Neurol Sci. 1993;  120 159-167
  CrossrefPubMedGoogle Scholar
• 27 SPSS Inc. .SPSS for Windows 95, V. 7.5. Chicago; SPSS Inc. 2000
  Google Scholar
• 28 Tan S Y, Pepys M B. Amyloidosis.  Histopathology. 1994;  25 403-414
  PubMedGoogle Scholar
• 29 Videen J S, Michaelis T, Pinto P, Ross B D. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study.  J Clin Invest. 1995;  95 788-793
  PubMedGoogle Scholar
• 30 Wischik C M, Harrington C R, Mukaetova-Ladinska E B, Novak M, Edwards P C, McArthur F K. Molecular characterization and measurement of Alzheimer's disease pathology: implications for genetic and environmental aetiology.  Ciba-Found-Symp. 1992;  169 268-293
  PubMedGoogle Scholar
• 31 Yano M, Moriuchi R, Kawasaki E, Watanabe M, Saito K, Takino H, Akazawa S, Miyamoto T, Nagataki S. Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin dependent diabetes mellitus.  J Autoimmun. 1995;  8 83-96
  PubMedGoogle Scholar

M. D. Bettina Zietz

Innere Medizin II, Kreiskrankenhaus Kelheim

93309 Kelheim

Germany

Phone: + 49944702160

Email: bettina.zietz@kkh-kelheim.de